Conditions: Lung Cancer, Non-Small Cell Non-Small-Cell Lung Cancer
Keywords: HYCAMTIN TAXOTERE non-small cell lung cancer NSCLC docetaxel topotecan Stage IIIB/IV Advanced
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 399
Healthy volunteers: no

Brief summary:
The purpose of this study is to compare the efficacy and safety of a weekly regimen of two FDA approved drugs in combination versus one FDA approved drug in subjects with advanced non-small cell lung cancer who have received one previous chemotherapy excluding TAXOTERE or HYCAMTIN.

Detailed description:

Arms:

Interventions: intervention 1: Topotecan/Docetaxel combination intervention 2: Docetaxel
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: